Loxo Oncology, Inc. (NASDAQ:LOXO) insider Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock in a transaction on Monday, September 18th. The shares were sold at an average price of $89.20, for a total value of $137,457.20. Following the completion of the transaction, the insider now owns 1,541 shares of the company’s stock, valued at $137,457.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Naarden Jacob Van also recently made the following trade(s):

  • On Tuesday, September 19th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $89.00, for a total value of $274,298.00.
  • On Monday, August 14th, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $73.73, for a total value of $113,617.93.
  • On Tuesday, August 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $73.57, for a total value of $226,742.74.

Shares of Loxo Oncology, Inc. (NASDAQ LOXO) opened at 86.81 on Friday. Loxo Oncology, Inc. has a 1-year low of $17.14 and a 1-year high of $91.32. The firm’s market capitalization is $2.59 billion. The firm has a 50-day moving average price of $77.03 and a 200-day moving average price of $61.97.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.15). During the same period in the previous year, the firm earned ($0.77) EPS. On average, analysts forecast that Loxo Oncology, Inc. will post ($4.54) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/insider-selling-loxo-oncology-inc-loxo-insider-sells-137457-20-in-stock/1582593.html.

A number of research analysts recently issued reports on LOXO shares. Morgan Stanley reiterated an “overweight” rating and issued a $91.00 target price on shares of Loxo Oncology in a report on Monday, June 19th. JMP Securities lowered Loxo Oncology from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $83.12 to $17.14 in a report on Tuesday, August 29th. They noted that the move was a valuation call. Stifel Nicolaus lifted their target price on Loxo Oncology from $52.00 to $71.00 and gave the company a “buy” rating in a report on Monday, June 5th. Citigroup Inc. upgraded Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 target price for the company in a report on Monday, June 5th. Finally, BTIG Research reiterated a “buy” rating and issued a $75.00 target price on shares of Loxo Oncology in a report on Tuesday, June 6th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $70.73.

A number of large investors have recently bought and sold shares of the business. FMR LLC boosted its position in Loxo Oncology by 12.1% in the 2nd quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock valued at $352,420,000 after buying an additional 472,814 shares during the last quarter. Wellington Management Group LLP boosted its position in Loxo Oncology by 34.4% in the 1st quarter. Wellington Management Group LLP now owns 2,437,872 shares of the biopharmaceutical company’s stock valued at $102,587,000 after buying an additional 623,730 shares during the last quarter. BlackRock Inc. boosted its position in Loxo Oncology by 20.6% in the 2nd quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after buying an additional 273,291 shares during the last quarter. Alliancebernstein L.P. boosted its position in Loxo Oncology by 50.2% in the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock valued at $75,121,000 after buying an additional 312,988 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Loxo Oncology by 24.7% in the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after buying an additional 181,471 shares during the last quarter.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.